DONECEPT table. 5 mg. 30 table
Danecept be used for the symptomatic treatment of mild to moderate forms of dementia Aytshaymer.
DONECEPT table. 5 mg. 30 table
DONECEPT WHAT IS AND WHAT IT IS USED
Donepezil is a medicinal product which inhibits an enzyme in the brain tissue of humans and thus favorably influence Alzheimer's disease.
Danetsept be used for the symptomatic treatment of mild to moderate forms of dementia Aytshaymer.
BEFORE YOU TAKE DONECEPT
Donecept not apply to:
Hypersensitivity to product, piperidine derivatives or any of the excipients;
With the use of this product please note the following:
Donetsept treatment should be supervised by a physician experienced in the diagnosis and treatment of Alzheimer's dementia. Diagnosis should be made according to generally accepted principles. Treatment should be initiated only caregiver who will regularly monitor drug intake. It continues as a benefit for the patient. It is necessary to make periodic re-evaluation of clinical response to therapy. In the absence of treatment effect should be considered interruption.
There is no known effect of severe Alzheimer's dementia, other types of dementia or other severe memory impairment
As a cholinesterase inhibitor, is likely to Donetsept enhances the effect of suktsinolholinovite relaxants during anesthesia
Due to its mechanism of action this group of drugs can slow the heart rate. In patients with "sick sinus syndrome knot" or other supraventricular cardiac conduction as a sino-atrial block and atrioventricular block Donetsept should be used with caution because of the risk of deepening the conduction disturbances.
The product is used with caution in patients with peptic ulcer disease in the past or those taking NSAIDs. No evidence of increased bleeding from the gastrointestinal tract or the occurrence of peptic ulcer.
The drug can cause difficulties in urination, although this was not observed in treatment Donetsept
Cholinomimetics can cause generalized epileptic fits other old can be a symptom of Alzheimer's disease.
It is possible exacerbation or unlock extrapyramidal symptoms with involuntary movements of the limbs, tongue, mimic muscles.
The product should be used with caution in patients with asthma or chronic obstructive pulmonary disease due to its cholinomimetic action.
Application of the product together with other inhibitors of acetylcholinesterase, agonists or antagonists of the cholinergic system should be avoided
Severe hepatic failure
There are no data on the use of Donetsept in patients with severe hepatic impairment
The product contains lactose, which makes it unsuitable for patients with lactase insufficiency, galactosaemia or glucose / galactose malabsorption.
Application Donecept and intake of food and beverages
No need for a special diet while taking this product.
Before taking any medicines, check with your doctor. Not found the fetus in studies in animals. Donetstsept should not be used during pregnancy.
Before taking any medicines, check with your doctor.
It is not known whether the product is excreted into breast milk and therefore breastfeeding should be discontinued during treatment.
Driving and operating machinery
Alzheimer's dementia may impair ability to drive or operate machinery. Donetsept can cause fatigue, dizziness and muscle cramps usually at the beginning of treatment or when increasing the dose.
Your doctor should carefully consider whether patients suffering from Alzheimer's can drive or operate machinery.
HOW TO USE DONECEPT
Always Donetsept following the instructions of your doctor.
Adults / Elderly
Treatment is initiated at 5 mg once daily. The product should be administered at bedtime. The dose of 5 mg should be administered at least one month to achieve steady and assessment of therapeutic response. The dose may be increased to 10 mg daily in a single dose. The maximum recommended dose is 10 mg.
Upon discontinuation of treatment, a gradual disappearance of the effect of the product. No evidence of deterioration after abrupt discontinuation of therapy.
Patients with renal and hepatic failure
Schedule is as above, because this condition does not affect the release of the product. Due to the possibility of increasing the concentration of Donetsept in mild to moderate hepatic impairment, dose escalation should be as tolerated. No data on use in patients with severe hepatic impairment.
Not recommended for use in children Donecept.
POSSIBLE SIDE EFFECTS
Infections and infestations:
Common - cold
Metabolism and nutrition disorders:
Common - anorexia
Common - hallucinations, anxiety, aggressive behavior
Nervous system disorders:
Common - sinkon, dizziness, insomnia
Uncommon - epileptic seizures
Rare - extrapyramidal symptoms
Uncommon - slow pulse
Rare - sino-atrial block, atrioventricular block
Common - diarrhea, vomiting, nausea, abdominal disorders
Uncommon - gastrointestinal bleeding, gastric and duodenal ulcer
Rare. hepatic impairment, including. hepatitis
Skin and subcutaneous tissue disorders:
Common - rash, itching
Disorders Musculoskeletal and connective tissue disorders:
Common - muscle cramps
Renal and urinary disorders:
Common - leakage of urine
Common - headache, fatigue, pain
Minimal increases in serum concentrations of muscle creatine kinase
Injury, poisoning, resulting from the interventions:
Common - accidents
The active substance is donepezil.
The other ingredients are lactose monohydrate, microcrystalline cellulose, corn starch, magnesium stearate
Composition of tablet coating tablets 5 mg: Opadry White, polyvinyl alcohol, titanium dioxide, macrogol 3350, talc
Composition of tablet coating 10 mg tablets: Opadry yellow, polyvinyl alcohol, titanium dioxide, macrogol 2250, talc.
One tablet contains 5 or 10 mg of donepezil hydrochloride